CSPC Innovation Pharmaceutical: Announcement on the Progress of Share Repurchase in July 2024.
CSPC Innovation Pharmaceutical: Announcement on the Progress of Using Part of the Idle Raised Funds for Cash Management
CSPC Innovation Pharmaceutical: The summary of the revised draft of the plan for issuing shares, paying cash to purchase assets, raising matching funds, and conducting related transactions by Shiyao Innovative Pharmaceutical Co., Ltd.
CSPC Innovation Pharmaceutical: Explanation of the purchase and sale of assets within the last 12 months prior to this trade.
CSPC Innovation Pharmaceutical: Announcement of the resolutions of the 16th meeting of the 6th Board of Directors.
CSPC Innovation Pharmaceutical: Explanation on this trade that complies with Article 11 and Article 43 of the Measures for the Administration of Major Asset Restructuring of Listed Companies.
CSPC Innovation Pharmaceutical: Announcement regarding the temporary non-holding of a shareholder meeting to deliberate on matters related to this trade.
CSPC Innovation Pharmaceutical: Announcement regarding the issuance of stocks, payment with cash to purchase assets, raising matching funds, adjusting the pricing benchmark date for related transactions, and revising the plan.
CSPC Innovation Pharmaceutical: Explanation that the adjustment of the pricing reference date for this trade proposal does not constitute a significant adjustment.
CSPC Innovation Pharmaceutical: This trade complies with the regulations of Article 4 of the Supervision Requirements for Major Asset Restructurings of Listed Companies in Compliance with the Guidelines for the Supervision of Listed Companies.
CSPC Innovation Pharmaceutical: Explanation of the confidentiality measures and system adopted for this trade.
CSPC Innovation Pharmaceutical: This trade complies with relevant regulations of the Securities Issuance and Registration Management Measures for Listed Companies.
CSPC Innovation Pharmaceutical: Regarding this trade, it is expected to constitute a significant asset restructuring under Article 12 of the "Management Measures for Major Asset Restructuring of Listed Companies", but it does not constitute a case of restructuring for listing under Article 13.
CSPC Innovation Pharmaceutical: The explanation of this transaction is in compliance with Article 18 and 21 of the Measures for the Continuous Supervision of Listed Companies on the Growth Enterprise Market (Trial), as well as Article 8 of the Shenzhen Stock Exchange's Rules for the Review of Major Asset Restructurings of Listed Companies.
CSPC Innovation Pharmaceutical: Announcement on Completing the Registration of Legal Representative Commercial Change and Obtaining a New Business License
CSPC Innovation Pharmaceutical: Explanation regarding the completeness, compliance, and effectiveness of the legal procedures and submission of legal documents for this trade.
CSPC Innovation Pharmaceutical: Regarding this trade, the relevant parties do not meet the requirements outlined in Article 12 of the "Guidelines for the Supervision of Listed Companies No. 7 - Supervision of Unusual Stock Trades Related to Major Asset Restructuring of Listed Companies" and Article 30 of the "Self-Regulatory Guidelines for Listed Companies in Shenzhen Stock Exchange No. 8 - Major Asset Restructuring (Revised in 2023)" and may not participate in the major asset restructuring of listed companies.
CSPC Innovation Pharmaceutical: Announcement of Resolutions of the Twelfth Meeting of the Sixth Supervisory Board
CSPC Innovation Pharmaceutical: Announcement on the Progress of Using Part of the Idle Raised Funds for Cash Management
CSPC Innovation Pharmaceutical: Shiyao Innovation Pharmaceutical Co., Ltd. issues shares and pays cash to purchase assets and raises matching funds, as well as a plan for related transactions (second revised draft).
No Data